# Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease

> **NCT00129753** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Hodgkin's Disease
- Lymphoma

## Interventions

- **DRUG:** Alemtuzumab (Campath-1H)

## Key facts

- **NCT ID:** NCT00129753
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2005-06-22
- **Primary completion:** 2006-09-05
- **Final completion:** 2006-09-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Terminated due to slow accrual.
- **Last updated:** 2018-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129753, "Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00129753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*